* Fulgent Genetics Inc FLGT.OQ FLGT.O is expected
to show a
fall in quarterly revenue when it reports results on May 3.
* The Temple City California-based company is expected to
report
a 24.6% decrease in revenue to $270.85 million from $359.43
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Fulgent Genetics
Inc is
for earnings of $3.86 per share. For the same quarter last year,
the company reported earnings of $6.59 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 1.2%
in the last three months.
* Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $104, above its last closing price of $54.88.
This summary was machine generated April 30 at 02:04 GMT. All
figures in US dollars unless otherwise stated